Caroline Geers

Caroline Geers

Auto-generated profile, based on publicly available information

Caroline Geers

Department of Pathology, Universitair Ziekenhuis Brussel, Brussels, Belgium

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 March 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
GCGang Chen
Gang Chen
IUIjeoma Umelo
Ijeoma Umelo
SLShasha Lv
Shasha Lv
ETErik Teugels
Erik Teugels
KFKarel Fostier
Karel Fostier
JGJacques De Grève
Jacques De Grève
Aberrant expression of microRNA-146a (miR-146a) has been reported to be involved in the development and progression of various types of cancers. However, its role in non-small cell lung cancer (NSCLC) has not been elucidated. The aim of this study was to investigate the contribution of miR-146a to various aspects of the malignant phenotype of human NSCLCs. In functional experiments, miR-146a suppressed cell growth, induced cellular apoptosis and inhibited EGFR downstream signaling in five NSCLC cell lines (H358, H1650, H1975, HCC827 and H292). miR-146a also inhibited the migratory capacity of these NSCLC cells. On the other hand, miR-146a enhanced the inhibition of cell proliferation by drugs targeting EGFR, including both TKIs (gefitinib, erlotinib, and afatinib) and a monoclonal antibody (cetuximab). These effects were independent of the EGFR mutation status (wild type, sensitizing mutation or resistance mutation), but were less potent compared to the effects of siRNA targeting of EGFR. Our results suggest that these effects of miR-146a are due to its targeting of EGFR and NF-κB signaling. We also found, in clinical formalin fixed paraffin embedded (FFPE) lung cancer samples, that low expression of miR-146a was correlated with advanced clinical TNM stages and distant metastasis in NSCLC (P<0.05). The patients with high miR-146a expression in their tumors showed longer progression-free survival (25.6 weeks in miR-146a high patients vs. 4.8 weeks in miR-146a low patients, P<0.05). miR-146a is therefore a strong candidate prognostic biomarker in NSCLC. Thus inducing miR-146a might be a therapeutic strategy for NSCLC.

1 April 2012 in Lung Cancer
Verified
Journal Article
Open access
JGJ. De Grève
J. De Grève
ETE. Teugels
E. Teugels
CGC. Geers
C. Geers
LDLore Decoster
Lore Decoster
DGD. Galdermans
D. Galdermans
DSD. Schallier
D. Schallier
Human epidermal growth factor receptor (HER)2/neu kinase domain mutations are found in approximately 1-4% of lung adenocarcinomas with a similar phenotype to tumors with epidermal growth factor receptor (EGFR) mutations. Afatinib is a potent irreversible ErbB family blocker. We determined the tumor genomic status of the EGFR and HER2 genes in non- or light smokers with lung adenocarcinoma in patients who were entered into an exploratory Phase II study with afatinib. Five patients with a non-smoking history and metastatic lung adenocarcinomas bearing mutations in the kinase domain of HER2 gene were identified, three of which were evaluable for response. Objective response was observed in all three patients, even after failure of other EGFR- and/or HER2-targeted treatments; the case histories of these patients are described in this report. These findings suggest that afatinib is a potential novel treatment option for this subgroup of patients, even when other EGFR and HER2 targeting treatments have failed.

1 October 2011 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
PDF file
KBKatrien Van Beneden
Katrien Van Beneden
CGCaroline Geers
Caroline Geers
MPMarina Pauwels
Marina Pauwels
Inge MannaertsInge Mannaerts
Inge Mannaerts
DVDierik Verbeelen
Dierik Verbeelen
CBChristiane Van Den Branden
Christiane Van Den Branden
Inhibitors of histone deacetylase (HDAC) have anti-inflammatory and antifibrotic effects in several organs and tissues, but their effect on the progression of renal disease is unknown. Here, we studied the effect of valproic acid in adriamycin-induced nephropathy in mice. Administration of valproic acid before kidney injury prevented the development of proteinuria and the onset of glomerulosclerosis. Even after postponing treatment until the peak of adriamycin-induced proteinuria, valproic acid rapidly decreased the quantity of proteinuria and attenuated the progression of renal disease. Valproic acid abrogated the decrease in glomerular acetylation observed during adriamycin-induced nephropathy. Furthermore, valproic acid attenuated the significant upregulation of profibrotic and proinflammatory genes, the deposition of collagen, and the infiltration of macrophages into the kidney. Valproic acid decreased glomerular apoptosis and proliferation induced by adriamycin. Ultrastructural studies further supported the protective effect of valproic acid on podocytes in this model. Taken together, these data suggest that HDACs contribute to the pathogenesis of renal disease and that HDAC inhibitors may have therapeutic potential in CKD.

1 November 2013 in European Journal of Paediatric Neurology
Verified
Journal Article
Closed access
SEScalais Emmanuel
Scalais Emmanuel
RCRonit Chafai
Ronit Chafai
RCRudy Van Coster
Rudy Van Coster
LBLutz Bindl
Lutz Bindl
CNChristian Nuttin
Christian Nuttin
LMLinda De Meirleir
Linda De Meirleir

1 September 2013 in Toxicology and Applied Pharmacology
Verified
Journal Article
Closed access
KBKatrien Van Beneden
Katrien Van Beneden
CGCaroline Geers
Caroline Geers
MPMarina Pauwels
Marina Pauwels
Inge MannaertsInge Mannaerts
Inge Mannaerts
KWKarl M. Wissing
Karl M. Wissing
Leo van GrunsvenLeo van Grunsven
Leo van Grunsven

9 December 2015 in Oncotarget
Verified
Journal Article
Open access
PDF file
IUIjeoma Umelo
Ijeoma Umelo
ANAmir Noeparast
Amir Noeparast
GCGang Chen
Gang Chen
MRMarleen Renard
Marleen Renard
CGCaroline Geers
Caroline Geers
JGJacques De Grève
Jacques De Grève
Identification of a novel HER3 activating mutation homologous to EGFR-L858R in lung cancer